Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells

Página do item simplificado
dc.creatorAna Delia Pinzón García
dc.creatorRubén Dario Sinisterra Millán
dc.creatorMaría Esperanza Cortés Segura
dc.creatorFredy Mesa
dc.creatorSandra Ramírez-Clavijo
dc.date.accessioned2023-12-12T18:45:53Z
dc.date.accessioned2025-09-08T23:59:17Z
dc.date.available2023-12-12T18:45:53Z
dc.date.issued2021
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.7717/peerj.12124
dc.identifier.issn2167-8359
dc.identifier.urihttps://hdl.handle.net/1843/61926
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofPeerJ
dc.rightsAcesso Aberto
dc.subjectBioquímica
dc.subjectBioengenharia
dc.subjectBiotecnologia farmacêutica
dc.subjectMamas - Câncer
dc.subjectCâncer - Tratamento
dc.subjectReceptores hormonais
dc.subjectTecnologia de liberação controlada
dc.subject.otherTamoxifen citrate
dc.subject.otherNanofibers
dc.subject.otherPolycaprolactone
dc.subject.otherBreast Cancer
dc.titlePolycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
dc.typeArtigo de periódico
local.citation.spagee12124
local.citation.volume9
local.description.resumoBreast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.
local.identifier.orcidhttps://orcid.org/0000-0002-8876-4907
local.identifier.orcidhttps://orcid.org/0000-0001-7656-1849
local.identifier.orcidhttps://orcid.org/0000-0002-0560-8491
local.publisher.countryBrasil
local.publisher.departmentFAO - DEPARTAMENTO DE ODONTOLOGIA RESTAURADORA
local.publisher.departmentICX - DEPARTAMENTO DE QUÍMICA
local.publisher.initialsUFMG
local.url.externahttps://peerj.com/articles/12124/

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells.pdf
Tamanho:
1.01 MB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG